EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Allmed Solutions Ltd (ALMD) fair value: what the stock is really worth

As of Oct 12, 2026: fair value of Allmed Solutions Ltd ILS 0.09, price ILS 0.30, upside -68.5%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · Il · ISIN IL0011014508

AS Thin data Oct 3, 2026

Allmed Solutions Ltd

ALMD · TA

Stretched ValuationStrong overvaluation with only moderate quality.

Quality 53/100
Fair value 0.0935 ILA · Strongly overvalued (−68.5%)
Weak Growth (revenue 5y −5.5 %/yr in ILA)
Negative free cash flow
Trails peers (2/8)
Narrow moat 5/100 · thin data
Thin data
⚠ Dilution
Watch Allmed Solutions Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.9290 ILA 0.2490 ILA Fair Value 0.0935 ILA Apr 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range 0.2490 ILA – 0.9290 ILA · fair‑value band 0.0765 ILA – 0.1190 ILA · the 0.2970 ILA price screens above the 0.0935 ILA fair value. Dashed = 300-day average. As of Oct 3, 2026.

Follow Allmed Solutions in your weekly email

Every Wednesday you see whether Allmed Solutions is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Allmed Solutions Ltd develops, manufactures, and markets minimally invasive products in various medical disciplines in Israel and internationally.

Show more

Allmed Solutions Ltd develops, manufactures, and markets minimally invasive products in various medical disciplines in Israel and internationally. The company offers drugs, biological products, and medical devices; and ProCatid system, a distal embolic protection system comprised of an independent filter unit that can be delivered, locked, and deployed on any commercially marketed guide wires. It is also involved in the development of a mitral valve regurgitation solution. The company was formerly known as Allium Medical Solutions Ltd. Allmed Solutions Ltd was incorporated in 2004 and is based in Or Akiva, Israel.

Stock analysis

Allmed Solutions Ltd (ALMD) currently trades at 0.2970 ILA, while our model-based Fair Value estimate is 0.0935 ILA, 68.5% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 83/100, which puts the evidence level at low.

Scenario range: 0.0765 ILA (bear) to 0.1190 ILA (bull), the price of 0.2970 ILA sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Allmed Solutions Ltd reported revenue of 0 ILS in FY2025 versus 5.5M ILS in FY2021. Reported net income was −14.1K ILS in FY2025.

Key figures

Market cap 30.1M ILA · EPS (TTM) −0.1500 ILA · Return on equity −46.9% · Return on assets (EBIT) −6.0% · Revenue (TTM) 283K ILA · Revenue growth (YoY) −97.6% · Free cash flow −12.1M ILA · Net cash 3.3M ILA.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).

What moves the price

The share trades about 25% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −69%, ALMD screens richer than that median.

Fair Value models

Bear 0.0765 ILA Fair Value 0.0935 ILA Bull 0.1190 ILA
Price 0.2970 ILA · Upside -68.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings 0.0900 ILA 0.1100 ILA 0.1500 ILA 75
NCAV (Graham) 0.1300 ILA 0.1800 ILA 0.2600 ILA 51
All 2 models by family
DCF Models
Owner Earnings 0.0900 ILA 0.1100 ILA 0.1500 ILA 75
Asset-Based
NCAV (Graham) 0.1300 ILA 0.1800 ILA 0.2600 ILA 51

Open the full fair value analysis →

Quality Score breakdown

Overall quality 53/100

Of which business quality 53 · Market factors (momentum, volatility) 36

Profitability 9
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 100
Earnings quality: real cash, not paper profit
Fin. Strength 61
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 59
Calm price path (market factor)
Momentum 25
Price trend over the last 3–12 months (market factor)
52W Momentum 27
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−42.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.5%
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−370.5% (2015) → −61.0% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ALMD screens overvalued: fair value 69% below the price. Compare with Abbott Laboratories, →

Compare Allmed Solutions Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 329 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 53 · Above median
Fair Value upside −68.5% · Bottom 25%
Profitability
Return on assets −24.7% · Bottom 25%
Operating margin (TTM) 0.0% · Below median
Growth and dividend
Revenue growth −97.6% · Bottom 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.39× · Cheapest 25%
P/S (TTM) 34.55× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $275.43 $302.97 +10% vs ALMD
Boston Scientific Corporation BSX $42.19 $46.41 +10% vs ALMD
DexCom, Inc DXCM $85.36 $93.90 +10% vs ALMD
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10% vs ALMD
STERIS plc STE $208.93 $229.82 +10% vs ALMD
GE HealthCare Technologies Inc GEHC $65.74 $70.37 +7% vs ALMD
Edwards Lifesciences Corporation EW $85.78 $81.94 −4% vs ALMD
Medtronic plc MDT $86.38 $65.61 −24% vs ALMD
Abbott Laboratories, ABT $100.10 $74.79 −25% vs ALMD
Koninklijke Philips N.V PHIA €21.87 €15.23 −30% vs ALMD

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Allmed Solutions Ltd · Fair Value
0.0935 ILA −69%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Allmed Solutions Ltd Fair Value". https://www.fairvalue-calculator.com/stock/ALMD

Frequently asked questions

Is Allmed Solutions Ltd (ALMD) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 0.0935 ILA versus a price of 0.2970 ILA, about −69% upside (overvalued).
What is the fair value of ALMD?
Our model-based fair value for Allmed Solutions Ltd is 0.0935 ILA (as of Oct 3, 2026), built from audited fundamentals. The current price: 0.2970 ILA.
What is the quality score of ALMD?
Allmed Solutions Ltd has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Allmed Solutions Ltd (ALMD)?
Our model-based price target is the fair value of 0.0935 ILA (as of Oct 3, 2026) from 2 valuation models. Cautious scenario 0.0765 ILA, optimistic scenario 0.1190 ILA. It is a calculation from audited fundamentals, not an analyst target.
What is the Allmed Solutions Ltd stock forecast for 2026?
Our models put fair value at 0.0935 ILA, about −69% upside versus a price of 0.2970 ILA (overvalued). Cautious scenario 0.0765 ILA, optimistic scenario 0.1190 ILA. The calculation is refreshed regularly with new filings.
What is the revenue of Allmed Solutions Ltd (ALMD)?
Allmed Solutions Ltd reported trailing-twelve-month revenue of about 283K ILS (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Allmed Solutions Ltd (ALMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Allmed Solutions Ltd it is 0.0935 ILA per share (as of Oct 3, 2026), against a price of 0.2970 ILA. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Allmed Solutions Ltd stock overvalued or undervalued in 2026?
As of Oct 3, 2026, ALMD trades above its calculated fair value: price 0.2970 ILA, fair value 0.0935 ILA, a gap of about −69% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALMD?
No. The price is what the market pays today (0.2970 ILA); the fair value is what the company's own numbers justify (0.0935 ILA). For Allmed Solutions Ltd the two are 0.2035 ILA per share apart. That gap is exactly why we show both numbers side by side.
How much is Allmed Solutions Ltd worth?
The market values Allmed Solutions Ltd at about 30.1M ILA (market capitalisation, as of Oct 3, 2026). Per share that is 0.2970 ILA; our models calculate a fair value of 0.0935 ILA per share.
What do the bullish and bearish scenarios say about ALMD?
Our models span a range for Allmed Solutions Ltd: cautious scenario 0.0765 ILA, base 0.0935 ILA, optimistic 0.1190 ILA per share (as of Oct 3, 2026, price 0.2970 ILA). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Allmed Solutions Ltd (ALMD)?
Balance-sheet figures for Allmed Solutions Ltd (as of Oct 3, 2026): return on equity −46.9%. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is ALMD from its 52-week high?
Allmed Solutions Ltd trades at 0.2970 ILA, about 25% below its 52-week high of 0.3970 ILA and 12% above the low of 0.2660 ILA (as of Oct 12, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0935 ILA is for.
Which stocks are comparable to Allmed Solutions Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Allmed Solutions Ltd stock attractive at the current price?
The data as of Oct 3, 2026: price 0.2970 ILA, calculated fair value 0.0935 ILA (−69%), Quality Score 53/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALMD calculated?
We run Allmed Solutions Ltd through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.0935 ILA, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Allmed Solutions Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Allmed Solutions Ltd (ALMD)?
The closing price on Oct 12, 2026 was 0.2970 ILA. Our model-based fair value is 0.0935 ILA, about −69% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Allmed Solutions Ltd right now?
The price sits above even our optimistic bull case (0.1190 ILA). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Allmed Solutions Ltd

How large is the market capitalisation of Allmed Solutions Ltd (ALMD)?
The market capitalisation of Allmed Solutions Ltd is 30.1M ILA. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Allmed Solutions Ltd (ALMD)?
Earnings per share at Allmed Solutions Ltd are −0.1500 ILA. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Allmed Solutions Ltd (ALMD)?
The return on equity (ROE) of Allmed Solutions Ltd is −46.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Allmed Solutions Ltd (ALMD)?
On an EBIT basis the return on assets of Allmed Solutions Ltd is −6.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Allmed Solutions Ltd (ALMD)?
Revenue at Allmed Solutions Ltd is growing −97.6% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Allmed Solutions Ltd (ALMD) generate?
The free cash flow of Allmed Solutions Ltd is −12.1M ILA (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Allmed Solutions Ltd (ALMD) hold?
Allmed Solutions Ltd holds more cash than debt, 3.3M ILA net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Allmed Solutions Ltd in the live analysis

One click puts Allmed Solutions Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.